In order to create an active pharmaceutical substance of the drug with prolonged action the modification of recombinant human granulocyte colony-stimulating factor GCSF (filgrastim) with polyethylene glycol (PEG, M 21.5 kDa) was conducted. A method for preparation of PEG-filgrastim designed for the development and scaling-up of the technological process of production was described. Modification of proteins with PEG was performed by selective covalent attachment of the molecule alpha-methyl-PEG-propionaldehyde to the alpha-amino group of the N-terminal methionine amino acid residue of the recombinant GCSF. The conditions of the reaction, which provide the desired product yield at least 85% of the total protein, also high protein concentration in the reaction mixture (more than 9 mg/mL) and reduce consumption of PEG in terms of terminal alpha-amino group of the protein was chosen. The data of RP HPLC and MALDI-mass spectrometry showed that the produced drug modified by the N-terminal residue and contains no more than 10% of products with a high degree of modification.

A new solubilization method of recombinant interferon beta-1b (IFNβ-1b) from the inclusion bodies was developed. This method allows to extract the target protein selectively in the solutions of different alcohols, such as ethanol, propanol and isopropanol. It was shown that the more effective IFNβ-1b solubilization was achieved in the 55% propanol solution. This method allowed to extract the target protein from inclusion bodies around 85-90%, and significantly reduced Escherichia coli content in the solubilizate, in comparison with standard methods.

No abstract

The venom of South American ant Paraponera clavata and its low-molecular-mass fraction were shown to possess insectotoxic and pore-forming activities. A number of glycophospholipid components were isolated from this ant venom by means of gel filtration and reversed-phase chromatography. Some of the compounds cause conductivity fluctuations in lipid bilayer membranes within the ranges 3-25 pS and 200-400 pS at concentrations of 10(-6) to 10(-7) M. N-Acetylglucosamine, a fatty acid, and phosphoric acid residues were found in their structures. A full structure, 3-myristoyl-2-acetamido-2-deoxy-alpha-D-glucopyranosyl phosphate, was elucidated for one of the compounds by the use of 1H, 13C, and 31P NMR spectroscopy and mass spectrometry.

Purpose. Increasing of treatment efficiency for patients with acute pancreatitis by improving objective means of determining the severity of acute pancreatitis.Materials and method. The study was based on a retrospective analysis of 130 cases of acute pancreatitis: 47 cases from «Krasnoyarsk Regional Clinical Hospital» and 83 cases from «Regional Interdistrict Clinical Hospital No 20 named after I.S. Berzon» in the period from 2015 to 2017. The raw data was pre-processed. In particular, different methods (median, linear regression) were used to fill the missing values in the observation matrix. The initial dataset contained features measured in various quantitative and categorical scales. For some features with a pronounced asymmetric distribution, a quantile transformation was applied to initial values. The quantile transformation allows features to be brought to a uniform distribution in order to reduce the risk of excluding significant features. Ridge regression was used in combination with an algorithm for sequential reduction of attribute space.Results. The classifier of three degrees of acute pancreatitis severity was developed. This classifier can help to determine better treatment tactics. During validation, the method of determining the severity of acute pancreatitis classification has proven to be effective. The average accuracy was 92% compared to the experts’ decisions. This procedure for constructing a classifier can be used as part of the basis to the medical decision support system.Conclusion. The results of this study will help to make the choice of a necessary starting therapy, assess the need for surgical intervention and in severe cases, prescribe enhanced antibacterial and detoxification therapy. This will predictably reduce the percentage of septic complications of acute pancreatitis, and consequently will reduce the frequency of fatal outcomes.